Systemic effects of thrombolytic drugs in acute myocardial infarction: Comparison of intravenous APSAC (BRL 26921) and intracoronary streptokinase
- 1 October 1987
- journal article
- Published by Elsevier in Fibrinolysis
- Vol. 1 (4), 225-230
- https://doi.org/10.1016/0268-9499(87)90040-3
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.Circulation, 1986
- Thrombolytic therapy in patients with acute myocardial infarction.Circulation, 1985
- Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarctionThrombosis Research, 1985
- Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921.Heart, 1985
- Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase.Circulation, 1985
- Intracoronary thrombolysis with an acylated streptokinase-plasminogen activator (BRL 26921) in patients with acute myocardial infarctionJournal of the American College of Cardiology, 1984
- Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency.Circulation, 1983
- On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921)Thrombosis Research, 1981
- Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapyNature, 1981
- Plasma heparin: A simple, one-sample determination of both effect and concentration based on the activated partial thromboplastin timeClinica Chimica Acta; International Journal of Clinical Chemistry, 1978